Cancer vaccines, which activate the immune system against a target antigen, are attractive
for prostate cancer, where multiple upregulated protein targets are identified. However …

Although the strategy of therapeutic vaccination for the treatment of prostate cancer has
advanced to and is available in the clinic (Sipuleucel-T), the efficacy of such therapy remains …

Cancer vaccines must activate multiple immune cell types to be effective against aggressive
tumours. Here we report the impact of the structural presentation of two antigenic peptides …

In the case of cancer immunotherapy, nanostructures are attractive because they can carry
all of the necessary components of a vaccine, including both antigen and adjuvant. Herein …

Cancer vaccine structure is emerging as an important design factor that offers tunable
parameters to enhance the targeted immune response. We report the impact of altering the …

Background Prostate-specific membrane antigen (PSMA) is a well characterized prostate-
specific tumor associated antigen. Its expression is elevated in prostate carcinoma …

For long‐term attack on tumor cells in patients with prostate cancer, induction of cytolytic T
cells is desirable. Several lineage‐specific target proteins are known and algorithms have …

Prostate cancer (PCa) is characterized as a “cold tumor” with limited immune responses,
rendering the tumor resistant to immune checkpoint inhibitors (ICI). Therapeutic messenger …

Among the few available mRNA delivery vehicles, lipid nanoparticles (LNPs) are the most
clinically advanced but they require cumbersome four components and suffer from …

Abstract Poly (lactic-co-glycolic) acid (PLGA) has been successfully used in drug delivery
and biomaterial applications, but very little attention has been directed towards the potential …